Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Patient-Reported Outcomes With First-Line Nivolumab + Cabozantinib vs Sunitinib in Patients With Advanced RCC
  2. Safety and Efficacy of Belzutifan for VHL-Associated RCC
  3. Predictive Biomarkers of Overall Survival in Patients With RCC Treated With Interferon Alpha ± Bevacizumab
  4. Final Overall Survival and Molecular Analysis in IMmotion151
  5. Cytoreductive Nephrectomy Following ICI-Based Dual Combination Therapy
  6. Angiogenesis Biomarkers and Clinical Outcomes With Cabozantinib and Everolimus in Patients With Metastatic RCC
  7. Germline Variants Identified in Patients With Early-Onset Renal Cell Carcinoma
  8. Toxicity and Clinical Outcomes in Full vs Reduced Starting-Dose Cabozantinib in Metastatic RCC
  9. Concomitant PPI Use Does Not Impact Survival Outcomes in Patients With Advanced RCC Taking ICIs
  10. CRP Flare–Response Predicts Efficacy of First-Line Anti–PD-1–Based Combination Therapy in Metastatic RCC

Elsewhere

Recently Updated